Whitehawk Therapeutics (WHWK) Common Equity (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Common Equity data on file, last reported at $116.2 million in Q1 2026.

• Common Equity for Q1 2026 came in at $116.2 million, down 47.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.2 million (down 47.6% YoY), and the FY2025 annual result was $136.3 million, up 159.75% from the prior year.
• Common Equity declined to $116.2 million in Q1 2026 per WHWK's latest filing, from $136.3 million in the prior quarter.
• Over five years, Common Equity peaked at $221.7 million in Q1 2025 and troughed at $52.5 million in Q4 2024.
• A 5-year average of $126.8 million and a median of $124.6 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity surged 797.34% in 2022, then plunged 50.11% in 2024.
• A 5-year view of Common Equity shows it stood at $158.4 million in 2022, then plunged by 33.58% to $105.2 million in 2023, then sank by 50.11% to $52.5 million in 2024, then soared by 159.75% to $136.3 million in 2025, then declined by 14.77% to $116.2 million in 2026.
• Business Quant data shows WHWK's Common Equity at $116.2 million in Q1 2026, $136.3 million in Q4 2025, and $157.2 million in Q3 2025.